| NCT07159763 | A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza | NOT_YET_RECRUITING | PHASE3 | 2025-09 | 2027-01 | 2027-01 |
| NCT06609460 | Study of CD388 for the Prevention of Influenza in Subjects Not at Risk for Influenza Complications | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-09-20 | 2025-09 | 2025-09 |
| NCT05619536 | Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects | COMPLETED | PHASE1 | 2022-10-18 | 2023-07-14 | 2023-07-14 |
| NCT05523089 | The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults | COMPLETED | PHASE2 | 2022-09-09 | 2023-07-17 | 2023-07-17 |
| NCT05285137 | Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects | COMPLETED | PHASE1 | 2022-03-14 | 2023-10-27 | 2023-10-27 |
| NCT03667690 | Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis | COMPLETED | PHASE3 | 2018-10-07 | 2021-10-07 | 2021-10-07 |
| NCT02734862 | CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension | COMPLETED | PHASE2 | 2016-07-26 | 2019-07 | 2019-06 |
| NCT02733432 | RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections | COMPLETED | PHASE2 | 2016-06-08 | 2016-12-23 | 2016-11-23 |
| NCT02551549 | An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects | COMPLETED | PHASE1 | 2015-09 | 2016-01 | 2016-01 |
| NCT02516904 | A Single Ascending Dose Study of CD101 IV in Healthy Subjects | COMPLETED | PHASE1 | 2015-07 | 2015-10 | 2015-10 |